| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1877 | Du-34569 Maleate | Antiviral agent against influenza A, parainfluenza Sendai, coxsackie A21, and rhinovirus |
|
| DCC1878 | Duocarmycin A | Irreversible DNA minor groove binding alkylating agent, disrupting the nucleic acid architecture and leading to tumor cell death |
|
| DCC1879 | Dutomycin | Anthracycline antibiotic from Streptomyces |
|
| DCC1880 | Dv-7028 | Selective 5-HT2A receptor antagonist |
|
| DCC1881 | Dv-7028 Hydrochloride | Potent and selective 5-HT 2A receptor antagonist |
|
| DCC1882 | Dw10075 | Novel potent and highly selective inhibitor of VEGFR, exhibiting antitumor activities both in vitro and in vivo. |
|
| DCC1883 | Dw-1350 | Novel and potent leukotriene B(4) receptor antagonist |
|
| DCC1884 | Dwn-723-23 | Novel Hsp70 agonist, showing no cellular toxicity and induced cellular stress response pathways |
|
| DCC1885 | Dx2-hsp70 Inhibitor-1 | Novel allosteric inhibitor of the tumor-promoting interaction between the oncogenic factor AIMP2-DX2 and HSP70 |
|
| DCC1886 | Dx-52-1 | Antitumor antibiotic |
|
| DCC1887 | Dy3002 | Novel Selective and Potent EGFR Inhibitor, Overcoming T790M-Mediated Resistance in Non-Small Cell Lung Cancer |
|
| DCC1888 | Dy428174 | Novel potent Inhibitor of PI3Kalpha |
|
| DCC1889 | E09241 | Novel OPG/RANKL upregulator, increasing OPG expression without affecting RANKL expression, promoting osteoblast differentiation while inhibiting osteoclast differentiation, regulating OPG expression through canonical Wnt/β-catenin signaling |
|
| DCC1890 | e2012-bpyne | γ-Secretase modulator (GSM) photoaffinity probe, revealing distinct allosteric binding sites on presenilin |
|
| DCC1891 | E235-1756 | Potent Activator of P53-Independent Cellular Senescence |
|
| DCC1892 | E3-ligase Degrader 10 | Novel XIAP BIR2 domain-binding degrader of E3 ubiquitin ligases |
|
| DCC1893 | E-5842 Citrate | Sigma1 receptor ligand and potential atypical antipsychotic |
|
| DCC1894 | Ea-b3a | Novel degrader of GST-α and GST-α-EGFP fusion proteins as well as endogenous GST-π in cells and lysates |
|
| DCC1895 | Ebi-13a | Highly potent and selective activator of isozymes CA-VA and CA-VII |
|
| DCC1896 | Ebmi-13b | Highly potent and selective activator of isozymes CA-VA and CA-VII |
|
| DCC1897 | Ebopiprant | Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist |
|
| DCC1898 | Ebov-in-c31 | Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties |
|
| DCC1899 | Ebselen Oxide | Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis |
|
| DCC1900 | Ebv Activator C60 | Novel EBV activator, well-performing EBV lytic cycle inducer |
|
| DCC1901 | Ecdsbb-in-12 | Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme |
|
| DCC1902 | Ecdsbb-in-9 | Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria |
|
| DCC1903 | Echinoside A | Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle |
|
| DCC1904 | Ecraprost | Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders |
|
| DCC1905 | Edoxaban Isomer | An impurity of Edoxaban, a novel inhibitor of factor Xa |
|
| DCC1906 | Eef2k-in-21i | Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways |
|
